Results 91 to 100 of about 33,791,512 (292)

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić, Christina Antza, Anastasios Poutachidis, Smaro Palaska, Elvira Meni Maria Gkrinia, Andrea Katrin Faour, Yusuf Ziya Sener, Seher Sener, Rehena Sultana   +8 more
wiley   +1 more source

Glucagon-Like Peptide-1 and Diabetes 2012

Experimental Diabetes Research, 2012
The present special issue was aimed at elucidating the role and the effects of glucagon-like peptide-1 (GLP-1) in type 2 diabetes. GLP-1 is a gastrointestinal hormone, mainly secreted after meals, capable of increasing glucose-stimulated insulin release and inhibits food intake.
MONAMI, MATTEO, Di Pasquale G, Rowzee A, ROTELLA, CARLO MARIA, MANNUCCI, EDOARDO   +4 more
openaire   +3 more sources

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Curcumin alone not combined with piperine exerts cardioprotective effects in pressure-overload rats by increasing glucagon-like peptide-1 receptor signaling and additional properties

Journal of Traditional and Complementary Medicine
Background and aim: Curcumin has shown significant cardiovascular protective effects. However, the low bioavailability limits its practical application. As a natural bioenhancer, piperine is expected to increase the bioavailability of curcumin, and then,
Xiao-jie Bai, Jun-tao Hao, Qi-long Feng, Chen-meng Guo, Min Pang, Jia Li, Jin Wang, Jian-feng Xing   +7 more
doaj   +1 more source

Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Aims The glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) semaglutide and liraglutide are approved for chronic weight management. Both drugs also have favourable effects on the risk of developing diabetes and cardiovascular disease (CVD) compared with placebo, but their comparative effectiveness for these outcomes is unclear.
Ethan J. Cannon, Wendy Wang, Faye L. Norby, Rob F. Walker, Shalini Kulasingam, Lisa S. Chow, Joel F. Farley, Pamela L. Lutsey   +7 more
wiley   +1 more source

Glucagon-like peptide-1 and satiety [PDF]

Nature, 1997
G, van Dijk, T E, Thiele, R J, Seeley, S C, Woods, I L, Bernstein   +4 more
openaire   +2 more sources

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado

Journal of Pharmaceutical Policy and Practice
Background High prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists for weight loss in the United States. This market has not been systematically studied. We conducted a pilot
Michael J. DiStefano, Mouna Dardouri, Gina D. Moore, Joseph J. Saseen, Kavita V. Nair   +4 more
doaj   +1 more source

Purslane Effect on GLP-1 and GLP-1 receptor in type 2 diabetes [PDF]

Electronic Physician, 2013
:Background: The aim of this study was to examine the effect of purslane seeds in glucagon-like peptide-1 concentration and glucagon-like peptide-1 receptor in women with diabetes.Methods: This was a quasi-experimental study. The population was consisted
Roja Daliri, Sara Heidarzadeh, Parvin Farzanegi, Mohammad Ali Azarbayjani   +3 more
doaj  

Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025

British Journal of Clinical Pharmacology, EarlyView.
Aims GLP‐1 medicines provide substantial cardio‐renal benefits for type 2 diabetes (T2D) and are increasingly used for weight loss. Most high‐income countries subsidize access for T2D with restrictions; use outside of these restrictions occurs through private prescriptions. Despite strong consumer demand, the extent of private access to GLP‐1 medicines
Michael O. Falster, Juliana de Oliveira Costa, Tamara Y. Milder, Joanne Carson, Cade Shadbolt, Brendon L. Neuen, Clare Arnott, Andrew Wilson, Min Jun, Nicole Pratt, Sallie‐Anne Pearson   +10 more
wiley   +1 more source

Therapeutic role of enterohormones in short bowel syndrome

Clinical Nutrition Open Science
Short bowel syndrome-associated chronic intestinal failure is the leading benign cause of long-term dependence on parenteral support in adults. Beyond the loss of absorptive surface area, intestinal resection profoundly modifies entero-hormonal signaling,
Lea Alioui, Palle Bekker Jeppesen, Tim Vanuytsel, Astrid Verbiest, Francisca Joly   +4 more
doaj   +1 more source